Disease Background, Patient Characteristics, and Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Each year, the VA manages more than 7,700 patients with newly diagnosed lung cancer.  Small Cell Lung Cancer accounts for about 13% of all patients with lung cancer but is characterized by more aggressive disease and a higher mortality rate than NSCLC.  Most SCLC patients are diagnosed in the metastatic stage, described as ES-SCLC.  For more than 30 years, the standard treatment has been combination platinum chemotherapy.  Recently, the approval of checkpoint inhibitors for the first-line treatment of ES-SCLC has improved survival for ES-SCLC patients. In this talk, we will describe the results of the Phase 3 CASPIAN study evaluating the use of durvalumab and chemotherapy in ES-SCLC.

Target Audience: Primary Care, Pulmonologists, Oncologists, Pharmacists and other Healthcare professional who care for patients with ES-SCLC